Clinical trials: Prolactin-Producing Pituitary Tumor
Merkel Cell Carcinoma, Islet Cell Carcinoma
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Conditions
- Merkel Cell Carcinoma, Islet Cell Carcinoma, Neuroendocrine Carcinoma, Pituitary Tumor
- Trial name
- NCT00003514
- Testing
- antineoplaston A10, antineoplaston AS2-1, alternative product therapy
- Where
- United States
- Sponsor
- Burzynski Research Institute
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer
- Trial name
- NCT00002947
- Testing
- indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Prolactinoma, Prolactin-Producing Pituitary Tumor
PRolaCT - Three Prolactinoma RCTs
This study aims to investigate if endoscopic trans-sphenoidal prolactinoma resection as a first line treatment, or as an equally valid second line treatment after a short (4-6 months) or long (>2 years) period of pretreatment…
- Trial name
- NCT04107480
- Testing
- Endoscopic trans-sphenoidal adenoma resection, Dopamine Agonists
- Where
- 3 sites in Netherlands
- Volunteers
- 880 people
- Sponsor
- Leiden University Medical Center
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Invasive Pituitary Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00601289
- Testing
- temozolomide, DNA methylation analysis, microarray analysis
- Sponsor
- Jonsson Comprehensive Cancer Center
Prolactin-Producing Pituitary Tumor
A Study of Pasireotide in People With Prolactinoma
The researchers are doing this study to find out whether pasireotide is an effective treatment for people with prolactinoma who cannot receive dopamine agonist therapy.
- Trial name
- NCT06295952
- Testing
- Pasireotide, SF-36 and HADS
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Metastatic Cancer
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
RATIONALE: Learning about the side effects of stereotactic radiosurgery in patients with brain tumors or other brain disorders may help doctors plan treatment and help patients live more comfortably.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity
- Trial name
- NCT00255671
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
Prolactinoma, Prolactin-Producing Pituitary Tumor
Validation of a Quality of Life Metric "Prolac-10"
This is a short-term validation study of a quality of life metric "Prolac-10" for patients diagnosed with a prolactinoma, undergoing new medical therapy.
- Conditions
- Prolactinoma, Prolactin-Producing Pituitary Tumor, Pituitary Tumor, Prolactinoma Macroadenoma
- Trial name
- Prolac-10 (NCT04106531)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ohio State University